文献速递药物相互作用特殊人群用药

瑞德西韦的药代动力学、药效学及药物相互作用特征

Pharmacokinetic, Pharmacodynamic, and Drug-Interaction Profile of Remdesivir, a SARS-CoV-2 Replication Inhibitor.
PubMed 文献 · Clin Pharmacokinet · 2021-03-30

瑞德西韦是一种每日一次给药的核苷RNA聚合酶抑制剂,已在多国获批用于成人和儿童重症COVID-19住院患者。本综述讨论了瑞德西韦的临床前药理学、临床药代动力学、药效学/浓度-QT分析、剂量选择依据及基于体外和健康志愿者数据的药物相互作用潜力。

要点

  • 瑞德西韦在健康受试者中呈线性药代动力学,主要代谢物GS-441524多次给药后蓄积约1.9倍。
  • 临床选用第1天200 mg负荷剂量、后续100 mg维持4或9天的方案。
  • 基于模型预测,瑞德西韦在治疗剂量下药物相互作用风险低。

核心结论

  • 瑞德西韦具有线性药代动力学特征,细胞内活性代谢物浓度高,支持所选临床给药方案。
  • 基于体外和I期数据,瑞德西韦在治疗剂量下药物相互作用风险低。

研究设计与样本

  • 本综述基于临床前药理学、临床药代动力学、药效学/浓度-QT分析、剂量选择依据及药物相互作用潜力评估。
  • 健康受试者单次2小时静脉输注瑞德西韦溶液,剂量范围3-225 mg。
  • 健康志愿者多次接受瑞德西韦150 mg每日一次,持续7或14天。

主要发现

  • 单次静脉给药后,瑞德西韦及其代谢物GS-704277和GS-441524呈现线性药代动力学。
  • 多次给药后,主要代谢物GS-441524在血浆中蓄积约1.9倍。
  • 细胞内活性三磷酸代谢物GS-443902浓度高,提示瑞德西韦有效转化为三磷酸形式。
  • 基于体外和I期数据的数学药物相互作用预测表明,瑞德西韦药物相互作用潜力低。
  • 生理药代动力学模型预测,在治疗剂量下瑞德西韦不是临床显著的药物代谢酶或转运体抑制剂。

关键数值与推荐

  • 瑞德西韦临床给药方案为第1天200 mg负荷剂量,后续100 mg维持剂量4或9天。
  • 健康受试者单次静脉输注瑞德西韦剂量范围3-225 mg。
  • 多次给药方案为瑞德西韦150 mg每日一次,持续7或14天。

临床怎么用

  • 瑞德西韦可用于成人和儿童重症COVID-19住院患者的治疗。
  • 临床可采用第1天200 mg负荷剂量、后续100 mg维持4或9天的方案。
  • 基于现有数据,瑞德西韦与其他药物合用时药物相互作用风险较低。

局限性

  • 药物相互作用潜力主要基于体外和I期健康志愿者数据及数学预测。
  • 临床药代动力学数据来自健康受试者,未在患者中全面验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Remdesivir (RDV, Veklury®) is a once-daily, nucleoside ribonucleic acid polymerase inhibitor of severe acute respiratory syndrome coronavirus 2 replication. Remdesivir has been granted approvals in several countries for use in adults and children hospitalized with severe coronavirus disease 2019 (COVID-19). Inside the cell, remdesivir undergoes metabolic activation to form the intracellular active triphosphate metabolite, GS-443902 (detected in peripheral blood mononuclear cells), and ultimately, the renally eliminated plasma metabolite GS-441524. This review discusses the pre-clinical pharmacology of RDV, clinical pharmacokinetics, pharmacodynamics/concentration-QT analysis, rationale for dose selection for treatment of patients with COVID-19, and drug-drug interaction potential based on available in vitro and clinical data in healthy volunteers. Following single-dose intravenous administration over 2 h of an RDV solution formulation across the dose range of 3-225 mg in healthy participants, RDV and its metabolites (GS-704277and GS-441524) exhibit linear pharmacokinetics. Following multiple doses of RDV 150 mg once daily for 7 or 14 days, major metabolite GS-441524 accumulates approximately 1.9-fold in plasma. Based on pharmacokinetic bridging from animal data and available human data in healthy volunteers, the RDV clinical dose regimen of a 200-mg loading dose on day 1 followed by 100-mg maintenance doses for 4 or 9 days was selected for further evaluation of pharmacokinetics and safety. Results showed high intracellular concentrations of GS-443902 suggestive of efficient conversion from RDV into the triphosphate form, and further supporting this clinical dosing regimen for the treatment of COVID-19. Mathematical drug-drug interaction liability predictions, based on in vitro and phase I data, suggest RDV has low potential for drug-drug interactions, as the impact of inducers or inhibitors on RDV disposition is minimized by the parenteral route of administration and extensive extraction. Using physiologically based pharmacokinetic modeling, RDV is not predicted to be a clinically significant inhibitor of drug-metabolizing enzymes or transporters in patients infected with COVID-19 at therapeutic RDV doses.

来源:Clin Pharmacokinet,查看原文。版权归原作者所有。

引用

  1. Humeniuk R, Mathias A, Kirby BJ, et al. Pharmacokinetic, Pharmacodynamic, and Drug-Interaction Profile of Remdesivir, a SARS-CoV-2 Replication Inhibitor. Clin Pharmacokinet. 2021. PMID: 33782830. doi:10.1007/s40262-021-00984-5

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。